{
    "clinical_study": {
        "@rank": "141264", 
        "acronym": "GGF2", 
        "arm_group": [
            {
                "arm_group_label": "GGF2", 
                "arm_group_type": "Experimental", 
                "description": "Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.\nEach patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.\nEach patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
            }
        ], 
        "brief_summary": {
            "textblock": "The study will examine midazolam pharmacokinetics following single dose administration of 3\n      planned dose levels of GGF2."
        }, 
        "brief_title": "A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "This drug-drug interaction (DDI) study evaluates the potential effect of intravenously\n      administered GGF2 on the elimination kinetics of midazolam."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  If female, must be at least 2 years post-menopausal or have bilateral oophorectomy,\n             hysterectomy or documented sterility\n\n          -  If male, must have documented sterility (by verbal report or previous vasectomy), or\n             if non-sterile, must agree to use barrier contraception for the entire duration of\n             the trial and until 3 months after the last dose of investigational product. Must\n             also agree not to donate sperm during the study and up to 3 months after the last\n             dose of investigational product\n\n          -  Stable coronary disease without unstable angina or acute coronary syndrome in the\n             last 6 months\n\n          -  All cardiac medications, specifically beta-blockers, renin-angiotensin system\n             inhibitors, aldosterone antagonists, hydralazine and nitrates are at a stable dose\n             (at least 4 weeks) prior to Day 1\n\n        Exclusion Criteria:\n\n          -  Any previous exposure to GGF2 or other neuregulins\n\n          -  Initiation or change of a prescription medication within the 2 weeks prior to Day 1,\n             and/or concomitant medication regimen is expected to change during the course of the\n             study\n\n          -  Known allergic reaction to midazolam, or any of the components of midazolam syrup\n             (including cherry flavoring), or components of GGF2 diluent\n\n          -  Known specific hepatic disease; total bilirubin >2 mg/dL, AST > 100 IU\n\n          -  History of hepatic impairment (hepatitis B and C)\n\n          -  Type I Diabetes\n\n          -  Documented stroke or transient ischemic attack (TIA) within 2 months of study\n             enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944683", 
            "org_study_id": "GGF2-CV-1007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "GGF2", 
                "intervention_name": "GGF2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "GGF2", 
                    "Placebo"
                ], 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "bdaly@ucsd.edu", 
                    "last_name": "Brendan Daly", 
                    "phone": "858-657-5267"
                }, 
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "University of California, San Diego"
                }, 
                "investigator": {
                    "last_name": "Barry H Greenberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "noli.raz@ocresearchcenter.com", 
                    "last_name": "Noli Raz", 
                    "phone": "714-263-7323"
                }, 
                "facility": {
                    "address": {
                        "city": "Tustin", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92780"
                    }, 
                    "name": "Orange County Research Center"
                }, 
                "investigator": {
                    "last_name": "Joel M Neutel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rstarnes@encoredocs.com", 
                    "last_name": "Rachel Starnes, BS", 
                    "phone": "904-730-0101"
                }, 
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32216"
                    }, 
                    "name": "Jacksonville Center for Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Michael J Koren, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rmcduffi@tulane.edu", 
                    "last_name": "Roberta McDuffie", 
                    "phone": "504-988-0299"
                }, 
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "Tulane University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Patrice Delafontaine, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lou.cappoli@duke.edu", 
                    "last_name": "Lou Cappoli", 
                    "phone": "919-684-4888"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke Clinical Research Unit"
                }, 
                "investigator": {
                    "last_name": "Robert J Noveck, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "chayzen@noccr.com", 
                    "last_name": "Colleen Hayzen, RN", 
                    "phone": "865-305-9100", 
                    "phone_ext": "6"
                }, 
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "New Orleans Center for Clinical Research (NOCCR)"
                }, 
                "investigator": {
                    "last_name": "William B Smith, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "koreresearch@deltamedicus.com", 
                    "last_name": "Donna Manns", 
                    "phone": "731-512-0104"
                }, 
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38351"
                    }, 
                    "name": "Kore Cardiovascular Research Institute"
                }, 
                "investigator": {
                    "last_name": "Elie Hage-Korban, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bobbye.wieman@vanderbilt.edu", 
                    "last_name": "Bobbye M Wieman, RN, BBA, CCRP", 
                    "phone": "615-936-1518"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Daniel J Lenihan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1b Study of Pharmacokinetic Interaction, Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure", 
        "overall_official": {
            "affiliation": "Acorda Therapeutics", 
            "last_name": "Enrique Carrazana, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety and tolerability of GGF2 IV infusion in patients with heart failure assessed by review of Treatment Emergent Adverse Events (TEAE)", 
                "safety_issue": "No", 
                "time_frame": "90 days (\u00b1 3 days)"
            }, 
            {
                "measure": "Pharmacokinetic (PK) parameter Area Under the Curve (AUC) of a single dose of midazolam when administered prior to and following a single IV infusion of GGF2 or Placebo", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 7"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944683"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline of 2D-Echocardiogram (2D-ECHO) or ECHO with contrast", 
                "safety_issue": "No", 
                "time_frame": "Visit 1 (day-14 to day-1) and visits 2-5 (day 8 through day 90 \u00b1 3 days)"
            }, 
            {
                "measure": "Change from baseline of the Six-Minute Walk Test (6MWT)", 
                "safety_issue": "No", 
                "time_frame": "Visit 1 (day-14 to day-1) and visits 3-5 (day 14 through day 90 \u00b1 3 days)"
            }, 
            {
                "measure": "Change from baseline of metabolic testing measuring maximum capacity of body to transport and use oxygen during incremental exercise (VCO2 and VO2 max)", 
                "safety_issue": "No", 
                "time_frame": "Visit 1 (day-14 to day-1) and visits 3-5 (day 14 through day 90 \u00b1 3 days)"
            }, 
            {
                "description": "MDASI is a questionnaire asking patients about the severity of their heart disease symptoms and impact of the symptoms on daily functioning during the past 24 hours.\nScale ranges from 0 (sympton has not been present) to 10 (the symptom was as bad as you can imagine it could be).", 
                "measure": "Change from baseline of the M.D. Anderson Symptom Inventory (MDASI) score", 
                "safety_issue": "No", 
                "time_frame": "Visit 1 (day-14 to day-1) and visits 3-5 (day 14 through day 90 \u00b1 3 days)"
            }
        ], 
        "source": "Acorda Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acorda Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}